Health Canada approved a second generic version of Novo Nordisk’s semaglutide‑based diabetes drug Ozempic on May 1 2026, following the first generic approval by Dr. Reddy’s Laboratories on April 29 2026. The new generic, produced by Canadian company Apotex, will enter the market after the brand’s patent expired in early January 2026, opening a window for competition.
Apotex will manufacture the semaglutide injectors in India through Orbicular Pharmaceutical Technologies, a facility chosen for its sterile injectable production capabilities. Although the product will be sold in Canada, the manufacturing location reflects the specialized infrastructure required for biologic drugs.
Canada is the first G7 country to approve a generic semaglutide, and the country represents about 4.1 % of global semaglutide revenue as of 2024. With a second generic now authorized, analysts expect the price of the drug to fall to roughly 50 % of the brand price, and potentially to 35 % if additional generics enter the market.
The approval increases competitive pressure on Novo Nordisk, potentially eroding its pricing power and market share in Canada. Novo has indicated it is considering a renamed, lower‑price version of Ozempic to compete with generics, a strategy that could mitigate revenue loss but also signals the company’s need to adapt to a more fragmented market.
Apotex’s generic is expected to reach Canadian pharmacies within weeks, offering patients and the healthcare system significant cost savings. The rapid availability underscores the urgency for Novo to respond strategically to preserve its market position.
This regulatory decision marks a pivotal shift in Canada’s diabetes treatment landscape, highlighting the growing role of generics in a high‑margin therapeutic area and signaling potential revenue headwinds for Novo Nordisk in the near term.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.